Tar DNA Binding Protein 43kDa (TDP43)

TAR DNA-binding protein is a cellular factor of 43 kDa that binds specifically to pyrimidine-rich motifs in TAR. Antibody to TDP-43 was used in gel retardation assays to demonstrate that endogenous TDP-43, present in HeLa nuclear extract, also bound to TAR DNA.

Although TDP-43 bound strongly to double-stranded TAR DNA via its ribonucleoprotein protein- binding motifs, it did not bind to TAR RNA extending from 1 to 80. TDP-43 is capable of modulating both in vitro and in vivo HIV-1 gene expression by either altering or blocking the assembly of transcription complexes that are capable of responding to Tat.TDP-43 is the major disease protein in both disorders.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPB951Hu01 Recombinant Tar DNA Binding Protein 43kDa (TDP43) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAB951Hu01 Polyclonal Antibody to Tar DNA Binding Protein 43kDa (TDP43) WB; IHC
MAB951Hu22 Monoclonal Antibody to Tar DNA Binding Protein 43kDa (TDP43) WB
MAB951Hu21 Monoclonal Antibody to Tar DNA Binding Protein 43kDa (TDP43) WB
Assay Kits SEB951Hu ELISA Kit for Tar DNA Binding Protein 43kDa (TDP43) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPB951Mu01 Recombinant Tar DNA Binding Protein 43kDa (TDP43) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAB951Mu01 Polyclonal Antibody to Tar DNA Binding Protein 43kDa (TDP43) WB; IHC; ICC; IP.
Assay Kits n/a CLIA Kit for Tar DNA Binding Protein 43kDa (TDP43) CLIA Kit Customized Service Offer
n/a ELISA Kit for Tar DNA Binding Protein 43kDa (TDP43) ELISA Kit Customized Service Offer
  1. "Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs."J. Virol. 69:3584-3596(1995) [PubMed] [Europe PMC] [Abstract]
  2. "TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein."Mol. Cell. Neurosci. 35:320-327(2007) [PubMed] [Europe PMC] [Abstract]
  3. "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
  4. "The full-ORF clone resource of the German cDNA consortium."BMC Genomics 8:399-399(2007) [PubMed] [Europe PMC] [Abstract]
  5. "The DNA sequence and biological annotation of human chromosome 1." Nature 441:315-321(2006) [PubMed] [Europe PMC] [Abstract]
  6. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
  7. , Submitted (MAR-2007) to UniProtKB
  8. "Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis."Science 314:130-133(2006) [PubMed] [Europe PMC] [Abstract]
  9. "Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping."EMBO J. 20:1774-1784(2001) [PubMed] [Europe PMC] [Abstract]
  10. "Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9."J. Biol. Chem. 276:36337-36343(2001) [PubMed] [Europe PMC] [Abstract]
  11. "Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions."Sci. Signal. 2:RA46-RA46(2009) [PubMed] [Europe PMC] [Abstract]
  12. "Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS." Nature 466:1069-1075(2010) [PubMed] [Europe PMC] [Abstract]
  13. "Initial characterization of the human central proteome."BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract]
  14. "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome."J. Proteomics 96:253-262(2014) [PubMed] [Europe PMC] [Abstract]
  15. "Mutations in the matrin 3 gene cause familial amyotrophic lateral sclerosis." Nat. Neurosci. 17:664-666(2014) [PubMed] [Europe PMC] [Abstract]
  16. "Solution structure of the RNA binding domains of TAR DNA-binding protein-43."Submitted (NOV-2005) to the PDB data bank
  17. "Solution structure of RRM domain in tar DNA-binding protein-43."Submitted (FEB-2009) to the PDB data bank
  18. "TDP-43 A315T mutation in familial motor neuron disease."Ann. Neurol. 63:535-538(2008) [PubMed] [Europe PMC] [Abstract]
  19. "TDP-43 mutation in familial amyotrophic lateral sclerosis."Ann. Neurol. 63:538-542(2008) [PubMed] [Europe PMC] [Abstract]
  20. "TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis." Lancet Neurol. 7:409-416(2008) [PubMed] [Europe PMC] [Abstract]
  21. "TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis."Nat. Genet. 40:572-574(2008) [PubMed] [Europe PMC] [Abstract]
  22. "TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis."Science 319:1668-1672(2008) [PubMed] [Europe PMC] [Abstract]
  23. "TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration."Ann. Neurol. 65:470-473(2009) [PubMed] [Europe PMC] [Abstract]
  24. "High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis."Hum. Mutat. 30:688-694(2009) [PubMed] [Europe PMC] [Abstract]
  25. "Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease."Hum. Mutat. 30:E974-E983(2009) [PubMed] [Europe PMC] [Abstract]
  26. "Genetic variants in the promoter of TARDBP in sporadic amyotrophic lateral sclerosis."Neuromuscul. Disord. 19:696-700(2009) [PubMed] [Europe PMC] [Abstract]
  27. "Large proportion of amyotrophic lateral sclerosis cases in Sardinia due to a single founder mutation of the TARDBP gene." Arch. Neurol. 68:594-598(2011) [PubMed] [Europe PMC] [Abstract]
  28. "High frequency of the TARDBP p.Ala382Thr mutation in Sardinian patients with amyotrophic lateral sclerosis."Clin. Genet. 81:172-178(2012) [PubMed] [Europe PMC] [Abstract]
  29. "Novel TARDBP mutations in Nordic ALS patients."J. Hum. Genet. 57:316-319(2012) [PubMed] [Europe PMC] [Abstract]